Agios Pharmaceuticals (AGIO) Announces Orphan Drug Designation Of AG-221 For Treatment Of Acute Myelogenous Leukemia
6/16/2014 7:45:23 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism (IEMs), today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for AG-221 for treatment of patients with acute myelogenous leukemia (AML). AG-221 is an oral, first-in-class IDH2 mutant inhibitor being evaluated in a Phase 1 clinical trial in patients with advanced hematologic malignancies that carry an IDH2 mutation.
Help employers find you! Check out all the jobs and post your resume.
comments powered by